Skip to main content
OpenTrials
Completed

NCT Number: NCT06848322

The Effects of 8-week Resistance and Aerobic Exercise on Anxiety, Depression, Sleep, Inhibitory Control in Young Adults With Smartphone Overdependence

The purpose of this study is to identify the effects of the resistance exercise and aerobic exercise on depression, anxiety, sleep, inhibitory control in young adult with smartphone overdependence

Completed

Looking for future studies?

Notify Me

Key information

Age range

20 year–29 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Seoul, Centennial Memorial Hall.

Dongdaemun, Seoul, South Korea

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Smartphone overdependent scale score of 24 ≥
  • No regular exercise in the past 3 months

Exclusion criteria

  • Unable to perform exercise
  • Patients with musculoskeletal disorders
  • Patients with cardiovascular diseases.

Treatment and study plan

Resistance exercise

Behavioral

Participants will perform resistance exercise for 8 weeks

Other names: aerobic exercise, control

Aerobic Exercise

Behavioral

Participants will perform aerobic exercise for 8 weeks

Control (placebo)

Other

Participants will maintain their usual lifestyle for 8 weeks.

Primary outcomes

  1. sleep duration

    Time frame: pre intervention: for 8days(before the intervention) / post intervention: for 8days(after the intervention)

    In this study, we will assess participants' sleep duration using a wrist-worn GENEActiv triaxial accelerometer (Activinsights, Cambridge, UK). Participants will be instructed to wear the device on their non-dominant wrist 24 hours a day for 8 days, except during contact sports that may pose a risk of injury. Sleep duration (minutes) is defined as the total time spent sleeping.

  2. Sleep efficiency

    Time frame: pre intervention: for 8days(before the intervention) / post intervention: for 8days(after the intervention)

    In this study, we will assess participants' sleep efficiency using a wrist-worn GENEActiv triaxial accelerometer (Activinsights, Cambridge, UK). Participants will be instructed to wear the device on their non-dominant wrist 24 hours a day for 8 days, except during contact sports that may pose a risk of injury. Sleep efficiency(%) is defined as the proportion of time spent asleep relative to time in bed

  3. Time in bed

    Time frame: pre intervention: for 8days(before the intervention) / post intervention: for 8days(after the intervention)

    In this study, we will assess participants' time in bed using a wrist-worn GENEActiv triaxial accelerometer (Activinsights, Cambridge, UK). Participants will be instructed to wear the device on their non-dominant wrist 24 hours a day for 8 days, except during contact sports that may pose a risk of injury. Time in bed (minutes) is defined as the total time spent in bed, including both sleep and wakefulness

  4. Sleep onset time

    Time frame: pre intervention: for 8days(before the intervention) / post intervention: for 8days(after the intervention)

    In this study, we will assess participants' sleep onset time using a wrist-worn GENEActiv triaxial accelerometer (Activinsights, Cambridge, UK). Participants will be instructed to wear the device on their non-dominant wrist 24 hours a day for 8 days, except during contact sports that may pose a risk of injury. Sleep onset time (hours and minutes) is defined as the time at which sleep begins.

  5. wake time

    Time frame: pre intervention: for 8days(before the intervention) / post intervention: for 8days(after the intervention)

    In this study, we will assess participants' sleep onset time using a wrist-worn GENEActiv triaxial accelerometer (Activinsights, Cambridge, UK). Participants will be instructed to wear the device on their non-dominant wrist 24 hours a day for 8 days, except during contact sports that may pose a risk of injury. Wake time (hours and minutes) is defined as the final wake-up time.

Secondary outcomes

  1. Depression

    Time frame: pre intervention(day 1), post intervention(day 57)

    Participants will visit the laboratory to complete the Beck Depression Inventory(BDI), a self-reported questionnaire assessing depressive symptoms. The BDI consists of 21 items, each scored on a scale from 0 to 3, with total scores ranging from 0 to 63. Higher scores indicate more severe depressive symptoms

  2. Anxiety

    Time frame: pre intervention(day 1), post intervention(day 57)

    Participants will visit the laboratory to complete the Beck Anxiety Inventory (BAI), a self-reported questionnaire assessing anxiety symptoms. The BAI consists of 21 items, each scored on a scale from 0 to 3, with total scores ranging from 0 to 63. Higher scores indicate more severe anxiety symptoms.

  3. Inhibition

    Time frame: pre intervention(day 1), post intervention(day 57)

    The Go/NoGo task will be used to measure the inhibition The measured variables will include reaction time (RT) and accuracy.

    At the beginning of the test, a series of stimulus characters will be presented in the center of the screen one by one. Each stimulus character will be displayed for 400 ms, with a random interval of 400-700 ms between stimuli.

    Before the test, participants will be informed that "L" is a Go stimulus and "C" is a NoGo stimulus. When "L" appears in the center of the screen, participants will be required to press the space bar key with their index finger as quickly and accurately as possible. When "C" appears, participants must not respond.

    The system will record the reaction time and accuracy for Go stimuli and the accuracy for NoGo stimuli. The total number of stimulus characters will be 240, consisting of 180 Go stimuli (75%) and 60 NoGo stimuli (25%).

Sponsors and collaborators

Lead sponsor

University of Seoul

Other

Registry information

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Feb 27, 2025
Registry last updated
Feb 27, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.